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Background 
Postpartum haemorrhage is one of the main causes of 
maternal death. Oxytocin and ergometrine are standard 
treatments. Misoprostol is a newer drug which is a 
potential alternative or addition to standard treatment. 
Inclusion criteria 
Studies:  
Randomized controlled trials in women with primary 
postpartum haemorrhage after delivery.   
Intervention: 
Uterotonic drug therapy versus control, placebo, or a 
different uterotonic drug regimen. 
Outcomes: 
Maternal mortality, serious maternal morbidity, or 
hysterectomy 
Measures of bleeding, such as blood loss. 
Side effects. 
Results 
Three trials of 462 women were included, all 
adequately concealed. 
Two trials of misoprostol versus placebo did not 
demonstrate an effect on maternal mortality or major 
morbidity.  
Rectal misoprostol was more likely to stop 
haemorrhage within 20 minutes (relative risk 0.18, 
95% confidence interval 0.07 to 0.76; 64 women, 1 
trial) and reduced the number of women needing 
additional uterotonic drugs (RR 0.18, 95% CI 0.07 to 
0.76; 64 women, 1 trial) when compared with a 
combination of syntometrine and oxytocin as first-line 
therapy.  
In two placebo-controlled trials, use of misoprostol 
(when bleeding persisted after treatment with 
conventional uterotonics) was associated with a 
significant reduction in the number of women with 
blood loss of 500 mL or more after enrolment (RR 
0.57, 95% CI 0.34 to 0.96; 397 women, 2 trials), but 
made no difference to blood loss over 1000 mL, 
average blood loss, or need for blood transfusion.  
Misprostol use in women with persistent bleeding 
after conventional uterotonic treatment was associated 
with increased shivering (RR 2.31, 95% CI 1.68 to 
3.18; 394 women, 2 trials) and maternal pyrexia (RR 
6.4, 95% CI 1.781 to 23.96; 392 women, 2 trials).  
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What drug should be used to treat primary postpartum haemorrhage? 
Injectable oxytocin or ergometrine. 
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Authors’ conclusions 
Implications for practice:  
There is not enough evidence to determine the best drug treatment for women with primary postpartum 
haemorrhage.  
Implications for research: 
Trials comparing different drug treatments for primary postpartum haemorrhage are needed to identify the best 
approach in terms of drug combinations, route, and dose. Trials are also needed to identify the best approaches to 
treatment where uterotonic drug treatment fails.  
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Misoprostol (after conventional uterotonic treatment) vs placebo: blood loss of 500 mL or more 
 
